Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors
Biodesix, Inc. is proud to announce that its CFO, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors.
254 Results
Biodesix, Inc. is proud to announce that its CFO, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors.
Biodesix announced today that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7.
Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at William Blair’s 43rd Annual Growth Stock Conference, which will be held from June 6-8, 2023.
Biodesix announced today that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test [NCT03766958]) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures.
Biodesix presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules.
Biodesix announces the designation of its Nodify CDT Test as an Advanced Diagnostic Laboratory Test by CMS, recognizing its innovation and clinical value in assessing the risk of malignancy in pulmonary nodules
INSIGHT study monitors 5,000 NSCLC patients for 3 years, validating VeriStrat® test. Biodesix: leading lung disease diagnostic solutions.
Biodesix reports Q1 2023 results: 86% increase in Core Lung Diagnostic revenue, record test numbers, and reaffirms 2023 financial outlook.
three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR)
Biodesix announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.